AI in China's pharmaceutical sector is reshaping drug discovery and licensing talks, as China drugmakers use better data, governance and faster pipelines.
China nuclear battery researchers reported a carbon-14 beta-voltaic prototype reaching microwatt output, pointing to long-life power for sensors and devices.
China biotech news on Beijing’s push to pair chip self-reliance with biotech scale, reshaping trials, devices and US-China cooperation in 2024.
Hong Kong surgeons reportedly completed a world-first robotic liver transplant from a living donor, raising questions about minimally invasive benefits, training, and oversight.
Akeso lung cancer drug trial results are cautiously boosting optimism for a US$20b market as investors track data quality, timelines, and next regulatory steps.
Hong Kong teams are testing GLP-1 weight-loss drugs for stroke treatment, tracking neurological recovery signals, trial design, and market impact today.
China biotech faces scrutiny after Tongji University disciplined cancer researcher Wang Ping for academic misconduct, prompting calls for tighter oversight.
Global competition for China’s biotechnology innovations is entering a more aggressive phase as venture capital firms increasingly shift their focus toward early stage scientific research rather than waiting for assets to reach commercialization. Investors, particularly from the United States, are embedding themselves directly
Hong Kong based CK Life Sciences is preparing to advance its cancer vaccine pipeline into mainland China using a faster clinical development pathway as the country expands support for early stage drug innovation. Backed by the business empire of Li Ka-shing, the company
Chinese biotechnology company Hangzhou Diagens Biotechnology is expanding the use of artificial intelligence driven chromosome testing to improve efficiency in in vitro fertilisation and strengthen its commercial growth strategy. The initiative comes as China faces declining birth rates and increasing demand for assisted
